title: Patients' assessment of adalimumab self-injection for Crohn's disease: a multicenter questionnaire survey (The PEARL Survey).
abstract: OBJECTIVE
  Adalimumab (ADA) is a self-injectable anti-tumor necrosis factor-α antibody used for treating Crohn’s disease (CD). Although self-injecting ADA may be convenient for patients, few reports have assessed patients receiving ADA self-injection therapy.
  
  
  METHODS
  We conducted a questionnaire survey involving outpatients on ADA self-injection therapy at four university hospitals. We analyzed the degree of satisfaction with and adherence to the self-injection therapy and performed sub-analyses.
  
  
  RESULTS
  Responses were obtained from 124 patients. Before treatment initiation, 38% patients replied that they were unwilling to accept the self-injection therapy. However, after treatment initiation, 75% patients were satisfied with the treatment. 66 patients previously treated with infliximab (IFX), the degree of treatment satisfaction was significantly higher in patients who felt burdened to the time required for IFX infusion than in those who had not felt burdened (P < 0.05). Patient adherence to ADA was high (85%). Multivariate analysis regarding adherence revealed that duration of disease (OR, 0.99), degree of treatment efficacy satisfaction (OR, 13.42), and schedule registration (OR, 7.95) were significant. Safety assessment results were within the range of those already reported.
  
  
  CONCLUSIONS
  ADA self-injection was thought to have good adherence and a safe administration method according to patients’ assessments.
authors.forename: Fumihito
authors.initials: F
authors.lastname: Hirai
authors.forename: Kenji
authors.initials: K
authors.lastname: Watanabe
authors.forename: Takayuki
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Masaki
authors.initials: M
authors.lastname: Iimuro
authors.forename: Noriko
authors.initials: N
authors.lastname: Kamata
authors.forename: Naoya
authors.initials: N
authors.lastname: Kubokura
authors.forename: Motohiro
authors.initials: M
authors.lastname: Esaki
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Yamagami
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Yano
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Hida
authors.forename: Shiro
authors.initials: S
authors.lastname: Nakamura
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Matsui
mesh_terms: D000068879:Adalimumab; D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D016009:Chi-Square Distribution; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D019538:Health Care Surveys; D006801:Humans; D007279:Injections, Subcutaneous; D007564:Japan; D016015:Logistic Models; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D015999:Multivariate Analysis; D016017:Odds Ratio; D017060:Patient Satisfaction; D012646:Self Administration; D011795:Surveys and Questionnaires; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab